Novartis gets FDA approval for expanded use of Tasigna

06/17/2010 | Wall Street Journal, The

The FDA authorized Novartis to promote Tasigna as a treatment for adults in earlier stages of Philadelphia chromosome-positive chronic myeloid leukemia. The drug was approved in October 2007 for patients whose disease had progressed or who failed to respond to other treatments, including Novartis' Gleevec.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC